Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich Sells 1,659 Shares

Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,659 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $10,435.11. Following the transaction, the chief financial officer now owns 191,419 shares in the company, valued at $1,204,025.51. This trade represents a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 10th, Robert Stefanovich sold 1,256 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total value of $6,129.28.

Cryoport Stock Down 4.9 %

Shares of NASDAQ CYRX opened at $6.17 on Wednesday. The stock has a market cap of $307.94 million, a P/E ratio of -1.83 and a beta of 1.67. The business’s fifty day simple moving average is $6.98 and its 200-day simple moving average is $7.43. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 12-month low of $4.58 and a 12-month high of $20.11.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to analysts’ expectations of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same period last year, the company earned ($0.29) EPS. As a group, equities analysts predict that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on CYRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim started coverage on Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Hedge Funds Weigh In On Cryoport

Several large investors have recently bought and sold shares of the business. Cadian Capital Management LP increased its holdings in Cryoport by 14.1% in the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock valued at $38,332,000 after buying an additional 609,021 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Cryoport by 11.0% during the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock worth $32,208,000 after purchasing an additional 409,353 shares during the last quarter. Fred Alger Management LLC grew its holdings in shares of Cryoport by 49.9% during the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after purchasing an additional 898,481 shares during the last quarter. Thematics Asset Management grew its holdings in shares of Cryoport by 176.2% during the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after purchasing an additional 1,087,800 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Cryoport by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company’s stock worth $10,870,000 after purchasing an additional 12,864 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.